Aplusia partners with biotech and pharmaceutical companies to unlock the value of their data. We build robust platforms and apply machine learning to turn large-scale biological datasets into actionable insights.
Understanding proteins at scale is central to modern drug discovery and diagnostics. Mass spectrometry-based proteomics now offers unprecedented sensitivity and throughput, driving demand across the field—from training structure prediction models and validating designed proteins to screening drug candidates and discovering novel targets.

We at Aplusia can help you realizing this potential with solid data infrastructure and the right analytical tools.

Aplusia

Org chart

Teams

Offices